tiprankstipranks
Pfizer (PFE)
NYSE:PFE
Holding PFE?
Track your performance easily

Pfizer (PFE) Stock Price & Analysis

32,304 Followers

PFE Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Earnings GrowthGuide shows clear path to earnings growth with expected adjusted diluted EPS to reach $2.90 at the midpoint in 2025.
Financial StabilityPfizer's current low valuation and healthy dividend yield are likely to establish a floor for the share price, providing some stability for investors.
Oncology InvestmentPfizer's oncology pipeline could generate good optionality in 2025+, spurring new investment opportunities.
Bears Say
Patent Expiries And CompetitionUpcoming patent expiries and competition create uncertainty for the long-term outlook of Pfizer's larger franchises.
Policy UncertaintyThe stock reflects a significant risk due to policy uncertainty, particularly impacting the US vaccines business.
Revenue GuidanceRevenues guidance mid-point was below expectations, implying potential challenges in achieving higher revenue growth.
---

Financials

Annual

Ownership Overview

0.03%18.30%0.45%60.21%
0.45% Other Institutional Investors
60.21% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

PFE FAQ

What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was $24.48 and its highest was $31.54 in the past 12 months.
    What is Pfizer’s market cap?
    Pfizer’s market cap is $147.85B.
      When is Pfizer’s upcoming earnings report date?
      Pfizer’s upcoming earnings report date is Feb 04, 2025 which is in 4 days.
        How were Pfizer’s earnings last quarter?
        Pfizer released its earnings results on Oct 29, 2024. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.614 by $0.446.
          Is Pfizer overvalued?
          According to Wall Street analysts Pfizer’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Pfizer pay dividends?
            Pfizer pays a Quarterly dividend of $1.687 which represents an annual dividend yield of 6.44%. See more information on Pfizer dividends here
              What is Pfizer’s EPS estimate?
              Pfizer’s EPS estimate is 0.46.
                How many shares outstanding does Pfizer have?
                Pfizer has 5,666,990,000 shares outstanding.
                  What happened to Pfizer’s price movement after its last earnings report?
                  Pfizer reported an EPS of $1.06 in its last earnings report, beating expectations of $0.614. Following the earnings report the stock price went down -1.395%.
                    Which hedge fund is a major shareholder of Pfizer?
                    Among the largest hedge funds holding Pfizer’s share is Diamond Hill Capital Management Inc. It holds Pfizer’s shares valued at 479M.
                      ---

                      Company Description

                      Pfizer

                      Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
                      ---

                      PFE Company Deck

                      ---

                      PFE Earnings Call

                      Q3 2024
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      Pfizer delivered strong Q3 2024 performance with significant revenue growth, driven by oncology and COVID-19 products. The company increased its full-year guidance and continued to make strategic advancements in its pipeline. However, challenges include the withdrawal of Oxbryta and uncertainties related to the Inflation Reduction Act.Read More>
                      ---

                      PFE Revenue Breakdown

                      52.29%52.29%25.59%19.88%2.24%
                      52.29% Primary Care
                      25.59% Specialty Care
                      19.88% Oncology
                      2.24% BUSINESS INNOVATION
                      tipranks
                      ---

                      PFE Stock 12 Month Forecast

                      Average Price Target

                      $30.40
                      ▲(12.97% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","37":"$37","27.25":"$27.3","30.5":"$30.5","33.75":"$33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,27.25,30.5,33.75,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,26.861538461538462,27.623076923076923,28.384615384615387,29.146153846153847,29.907692307692308,30.66923076923077,31.43076923076923,32.19230769230769,32.95384615384616,33.715384615384615,34.47692307692308,35.238461538461536,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,26.430769230769233,26.761538461538464,27.092307692307692,27.423076923076923,27.753846153846155,28.084615384615386,28.415384615384614,28.746153846153845,29.076923076923077,29.407692307692308,29.738461538461536,30.069230769230767,{"y":30.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.1,26.015384615384615,25.930769230769233,25.846153846153847,25.761538461538464,25.676923076923078,25.592307692307692,25.50769230769231,25.423076923076923,25.338461538461537,25.253846153846155,25.16923076923077,25.084615384615386,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.56,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.02,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.08,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.58,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.96,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Bristol-Myers Squibb
                      Eli Lilly & Co
                      Johnson & Johnson
                      Merck & Company
                      AbbVie

                      Best Analysts Covering PFE

                      1 Year
                      Vamil DivanGuggenheim
                      1 Year Success Rate
                      27/35 ratings generated profit
                      77%
                      1 Year Average Return
                      +5.60%
                      reiterated a buy rating 2 months ago
                      Copying Vamil Divan's trades and holding each position for 1 Year would result in 77.14% of your transactions generating a profit, with an average return of +5.60% per trade.
                      Popular Stocks
                      ---
                      What am I Missing?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis